Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

0HF9 ·

Amicus Therapeutics, Inc. (0HF9) is a Medical pharmaceuticals company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Amicus Therapeutics, Inc. in 2026.

Earnings calendar

Next earnings date

—

Not scheduled

EPS estimate

—

Revenue estimate

—

Past earnings

13 May 2026
EPS actual
—
estimate 0.05
Revenue actual
—
estimate 163.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
20 Feb 2026
EPS actual
0.01 (-86.0%)
estimate 0.07
Revenue actual
185.2M (+2.6%)
estimate 180.5M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
04 Nov 2025
EPS actual
0.06 (+55.6%)
estimate 0.04
Revenue actual
169.1M (+2.0%)
estimate 165.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Sector
Healthcare
Industry
Medical pharmaceuticals
Country
United States
Exchange
London Exchange
CEO
Bradley L. Campbell
Employees
499
IPO date
29 Jan 2018
ISIN
US03152W1099
Website
amicusrx.com

Frequently asked questions

What was Amicus Therapeutics, Inc.'s most recent earnings date?

Amicus Therapeutics, Inc. (0HF9) last reported earnings on May 13, 2026.

Where is Amicus Therapeutics, Inc. stock listed?

Amicus Therapeutics, Inc. (0HF9) is listed on London Exchange.